Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A disease believed to be caused by a viral illness that triggers degeneration of the nerve cells in the substantia nigra. Overall, this degeneration leads to clinical parkinsonism.
Features include very common findings: Resting tremor; and common findings: Fever, Slowness of movement (bradykinesia), Drowsiness, and Cogwheel rigidity and others. 41 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 17 | Resting tremor, Slowness of movement (bradykinesia), Cogwheel rigidity |
1 FDA-approved treatment is available for postencephalitic Parkinson disease, including CARBIDOPA TABLETS (CARBIDOPA, approved 1977).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
Phenotype severity distribution: 1 very common feature, 10 common features.
No clinical trials have been registered for postencephalitic Parkinson disease.
7 publications have been identified in PubMed for postencephalitic Parkinson disease. Kisho has analyzed 5 by research type. Research spans Review / Meta-Analysis (40%), Basic Science / Preclinical (40%), and Case Report / Case Series (20%).
Bonomo N (2026). [PMID: 42218820](https://pubmed.ncbi.nlm.nih.gov/42218820/). *J ECT*. [Case Report / Case Series]
Strobel S (2024). [PMID: 39329695](https://pubmed.ncbi.nlm.nih.gov/39329695/). *Cells*. [Basic Science / Preclinical]
Martini M (2024). [PMID: 38059885](https://pubmed.ncbi.nlm.nih.gov/38059885/). *Journal of the history of the neurosciences*. [Review / Meta-Analysis]
Brainin M (2024). [PMID: 38745394](https://pubmed.ncbi.nlm.nih.gov/38745394/). *European journal of neurology*. [Review / Meta-Analysis]
Tanaka H (2024). [PMID: 39036836](https://pubmed.ncbi.nlm.nih.gov/39036836/). *Neuropathology and applied neurobiology*. [Basic Science / Preclinical]
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 10:40 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Eyes
3 |
Abnormal eye movements (abnormality of eye movement), Slow saccadic eye movements, Bilateral ptosis |
Muscles | 2 | Generalized muscle weakness, Hyperactive deep tendon reflexes |
Digestive system | 2 | Vomiting, Difficulty swallowing (dysphagia) |
Metabolism | 1 | Fever |
Lungs and breathing | 1 | Abnormal respiratory system physiology |
Bones and joints | 1 | Excessive outward curvature of the upper spine (kyphosis) |
Head and neck | 1 | Fixed facial expression |
Cognition | 1 | Abnormality of mental function |
CARBIDOPA
CARBIDOPA TABLETS |
— |
1977 |
Available |
View trials for postencephalitic Parkinson disease